Cargando…

Clinical efficacy of Daikenchuto for gastrointestinal dysfunction following colon surgery: a randomized, double-blind, multicenter, placebo-controlled study (JFMC39-0902)

OBJECTIVE: This exploratory trial was performed to determine whether Daikenchuto accelerates recovery of gastrointestinal function in patients undergoing open colectomy for colon cancer. METHODS: A total of 386 patients undergoing colectomy at 1 of the 51 clinical trial sites in Japan from January 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Katsuno, Hidetoshi, Maeda, Koutarou, Kaiho, Takashi, Kunieda, Katsuyuki, Funahashi, Kimihiko, Sakamoto, Junichi, Kono, Toru, Hasegawa, Hirotoshi, Furukawa, Yoshiyuki, Imazu, Yoshihiro, Morita, Satoshi, Watanabe, Masahiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485603/ https://www.ncbi.nlm.nih.gov/pubmed/25972515 http://dx.doi.org/10.1093/jjco/hyv056

Ejemplares similares

Daikenchuto accelerates the recovery from prolonged postoperative ileus after open abdominal surgery: a subgroup analysis of three randomized controlled trials
por: Kono, Toru, et al.
Publicado: (2019)

The Japanese Extracted Herbal Medicine Daikenchuto Increases the Contractile Activity of the Internal Anal Sphincter Muscle in Conscious Dogs
por: Maeda, Kotaro, et al.
Publicado: (2020)

Randomized phase III trial comparing surgery alone to UFT + PSK for stage II rectal cancer (JFMC38 trial)
por: Okuno, Kiyotaka, et al.
Publicado: (2017)

Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer
por: Suto, Takeshi, et al.
Publicado: (2017)

Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study
por: Tomita, Naohiro, et al.
Publicado: (2019)

Cost-effectiveness of 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer: preplanned cost-effectiveness analysis of the JFMC37-0801 study
por: Shibahara, Hidetoshi, et al.
Publicado: (2022)

No Significant Effect of Daikenchuto (TJ-100) on Peritoneal IL-9 and IFN-γ Levels After Pancreaticoduodenectomy
por: Maeda, Hiromichi, et al.
Publicado: (2020)

Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003)
por: Tanaka, Hiroaki, et al.
Publicado: (2017)

Complementary and synergistic therapeutic effects of compounds found in Kampo medicine: analysis of daikenchuto
por: Kono, Toru, et al.
Publicado: (2015)

Traditional Japanese Medicine Daikenchuto Improves Functional Constipation in Poststroke Patients
por: Numata, Takehiro, et al.
Publicado: (2014)

Enhanced anastomotic healing by Daikenchuto (TJ-100) in rats
por: Wada, Toshiaki, et al.
Publicado: (2018)

Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101)
por: Matsusaka, Satoshi, et al.
Publicado: (2015)

Intestinal, portal, and peripheral profiles of daikenchuto (TU-100)'s active ingredients after oral administration
por: Watanabe, Junko, et al.
Publicado: (2015)

Prognostic factors in patients with high-risk stage II colon cancer after curative resection: a post hoc analysis of the JFMC46-1201 trial
por: Sugimoto, Kiichi, et al.
Publicado: (2023)

Erratum to: Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101)
por: Matsusaka, Satoshi, et al.
Publicado: (2015)

Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201)
por: Sadahiro, Sotaro, et al.
Publicado: (2022)

Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane‐ and trastuzumab‐naïve patients with HER2‐positive, previously treated, advanced, or recurrent gastric cancer (JFMC45‐1102)
por: Nishikawa, Kazuhiro, et al.
Publicado: (2016)

Gene Transfer in Leptolyngbya sp. Strain BL0902, a Cyanobacterium Suitable for Production of Biomass and Bioproducts
por: Taton, Arnaud, et al.
Publicado: (2012)

Daikenchuto, a traditional Japanese herbal medicine, promotes colonic transit by inducing a propulsive movement pattern
por: Kubota, Kunitsugu, et al.
Publicado: (2019)

Protective Effect of Daikenchuto on Dextran Sulfate Sodium-Induced Colitis in Mice
por: Matsunaga, Takaharu, et al.
Publicado: (2017)

Efficacy and Safety of Daikenchuto for Constipation and Dose-Dependent Differences in Clinical Effects
por: Hirose, Tatsuya, et al.
Publicado: (2018)

Daikenchuto (TU‐100) shapes gut microbiota architecture and increases the production of ginsenoside metabolite compound K
por: Hasebe, Takumu, et al.
Publicado: (2016)

Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials
por: Maeda, Hiromichi, et al.
Publicado: (2017)

Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial)
por: Kotaka, Masahito, et al.
Publicado: (2015)

Effect of Traditional Japanese Medicine, Daikenchuto (TJ-100) in Patients With Chronic Constipation
por: Horiuchi, Akira, et al.
Publicado: (2010)

Depolarizing Effects of Daikenchuto on Interstitial Cells of Cajal from Mouse Small Intestine
por: Kim, Hyungwoo, et al.
Publicado: (2017)

Daikenchuto (TU‐100) alters murine hepatic and intestinal drug metabolizing enzymes in an in vivo dietary model: effects of gender and withdrawal
por: Nobutani, Kentaro, et al.
Publicado: (2017)

A Pilot Study of the Effect of Daikenchuto on Rectal Sensation in Patients with Irritable Bowel Syndrome
por: Acosta, Andres, et al.
Publicado: (2016)

Daikenchuto significantly improves stool consistency and lower gastrointestinal symptoms in patients with chronic constipation
por: Manabe, Noriaki, et al.
Publicado: (2023)

A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902)
por: Ogata, Yutaka, et al.
Publicado: (2015)

Cattle with the BoLA class II DRB3*0902 allele have significantly lower bovine leukemia proviral loads
por: HAYASHI, Takumi, et al.
Publicado: (2017)

Daikenchuto (Da-Jian-Zhong-Tang) ameliorates intestinal fibrosis by activating myofibroblast transient receptor potential ankyrin 1 channel
por: Hiraishi, Keizo, et al.
Publicado: (2018)

The effects of the herbal medicine Daikenchuto (TJ-100) after esophageal cancer resection, open-label, randomized controlled trial
por: Nishino, Takeshi, et al.
Publicado: (2017)

P09.02 Impact of COVID-19 in Portuguese Lung Cancer Patients’ Treatment: Portuguese Lung Cancer Study Group Survey
por: Estevinho, F., et al.
Publicado: (2021)

Time-, Sex-, and Dose-Dependent Alterations of the Gut Microbiota by Consumption of Dietary Daikenchuto (TU-100)
por: Miyoshi, Jun, et al.
Publicado: (2018)

Daikenchuto attenuates visceral pain and suppresses eosinophil infiltration in inflammatory bowel disease in murine models
por: Kogure, Yoko, et al.
Publicado: (2020)

Development and validation of an analysis method for pesticide residues by gas chromatography–tandem mass spectrometry in Daikenchuto
por: Saegusa, Hirokazu, et al.
Publicado: (2021)

Therapeutic effect and mechanism of Daikenchuto in a model of methotrexate-induced acute small intestinal mucositis
por: Li, Peilin, et al.
Publicado: (2023)

Severity, Course, and Predictors of Sleep Disruption Following Hematopoietic Cell Transplantation: A Secondary Data Analysis from the BMT CTN 0902 Trial
por: Jim, Heather S.L., et al.
Publicado: (2018)

Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein–Protein Interaction
por: Ketcham, John M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o98544gpjf049vh3uf24k1khis